Moberg Pharma AB (publ) (STO:MOB)
10.10
-0.34 (-3.26%)
May 26, 2026, 5:29 PM CET
Moberg Pharma AB Revenue
Moberg Pharma AB had revenue of 4.92M SEK in the quarter ending March 31, 2026, with 27.24% growth. This brings the company's revenue in the last twelve months to 14.59M, up 13.47% year-over-year. In the year 2025, Moberg Pharma AB had annual revenue of 13.54M with 37.99% growth.
Revenue (ttm)
14.59M
Revenue Growth
+13.47%
P/S Ratio
32.53
Revenue / Employee
2.92M
Employees
6
Market Cap
474.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.54M | 3.73M | 37.99% |
| Dec 31, 2024 | 9.81M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 207.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.66M |
| Cinclus Pharma Holding AB | 67.51M |
| Nanexa AB | 54.32M |
| Enzymatica AB | 53.06M |
| Cereno Scientific AB | 44.27M |
| Newbury Pharmaceuticals AB | 32.78M |
| Orexo AB | 17.80M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
Moberg Pharma AB News
- 14 days ago - Moberg Pharma AB Quarterly report: Q1 2026 - Filings
- 2 months ago - Moberg Pharma AB Slides: FY 2026 - Filings
- 3 months ago - Moberg Pharma AB Quarterly report: Q4 2025 - Filings
- 3 months ago - Moberg Pharma AB Annual report: Q4 2025 - Filings
- 3 months ago - Moberg Pharma AB Slides: Investor presentation - Filings
- 7 months ago - Moberg Pharma AB Quarterly report: Q3 2025 - Filings
- 7 months ago - Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential - PRNewsWire
- 10 months ago - Moberg Pharma AB Quarterly report: Q2 2025 - Filings